Dr. Shah on the Use of Tisagenlecleucel in Pediatric ALL

Video

Bijal D. Shah, MD, associate professor, Department of Malignant Hematology, Moffitt Cancer Center, discusses the use of CAR T-cell therapy in patients with pediatric acute lymphoblastic leukemia (ALL).

Bijal D. Shah, MD, associate professor, Department of Malignant Hematology, Moffitt Cancer Center, discusses the use of CAR T-cell therapy in patients with pediatric acute lymphoblastic leukemia (ALL).

Tisagenlecleucel (Kymriah) is approved for pediatric and young adult patients ≤25 years of age with B-cell precursor ALL that is refractory or in second or later relapse. The therapy has been particularly beneficial to patients with extramedullary disease, says Shah, particularly in those with refractory central nervous system disease. This is an area where the monoclonal antibodies blinatumomab (Blincyto) and inotuzumab ozogamicin (Besponsa) have shown much efficacy.

Any patient with refractory disease, irrespective of disease origin, could derive benefit from the CD19-directed CAR T-cell therapy. However, there are some limitations, cautions Shah. For example, the product is only approved for use in patients with B-cell ALL, not those with T-cell ALL. To that end, Autolus Therapeutics is developing a CAR T-cell product that may prove to be beneficial in this subset. Additionally, researchers are evaluating agents targeting CD5, CD7, and CD1A, which could fill the current absence of effective targeted therapies for patients with T-cell ALL, concludes Shah.

Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.